AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis.
Kim DG, Choi Y, Lee Y, Lim S, Kong J, Song J, Roh Y, Harmalkar DS, Lee K, Goo JI, Cho HY, Mushtaq AU, Lee J, Park SH, Kim D, Min BS, Lee KY, Jeon YH, Lee S, Lee K, Kim S.
Kim DG, et al. Among authors: jeon yh.
Nat Commun. 2022 May 11;13(1):2572. doi: 10.1038/s41467-022-30149-2.
Nat Commun. 2022.
PMID: 35546148
Free PMC article.
Here, we report that AIMP2-DX2, a variant of the tumor suppressor AIMP2 (aminoacyl-tRNA synthetase-interacting multi-functional protein 2), acts as a cancer-specific regulator of KRAS stability, augmenting KRAS-driven tumorigenesis. AIMP2-DX2 specifically binds to the hypervariab …
Here, we report that AIMP2-DX2, a variant of the tumor suppressor AIMP2 (aminoacyl-tRNA synthetase-interacting multi-functional protein 2), …